CAMBRIDGE, Md., Oct. 9, 2020 /PRNewswire/ — OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in kids and adults, today announced the appointment of Jutta Wanner, Ph.D., as its Chief Technology Officer. She is continuing to support the Next Generation Antibody Drug Conjugate (ADC) technology that she helped to develop at BlinkBio, which OS Therapies recently in-licensed.
At BlinkBio, Dr. Wanner was a member of the leadership team setting research strategy for chemistry and biology, developed business, and science focused company strategies. She developed the Medical and Computational Chemistry Group, represented Chemistry and Discovery in Board of Director, Scientific Advisory Board and Partnering/Collaboration meetings. Specifically, Dr. Wanner:
Established the Tunable Drug Conjugate (TDC) platform technology to deliver next generation Drug Conjugates
Developed the lead TDC program which targets Folate Receptor alpha (FRa) which